The other day, we hosted an hourlong webinar on how to analyze clinical trials to best spot red flags before they cause trouble. The response was terrific and we thank you for your interest.

But because we only had a limited time for the webinar, we weren’t able to address all of your questions. We have collected some more and compiled the responses below.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Clear and concise answers to some great additional questions.
    Will be reading those SECs even more diligently.
    Just wondering what percentage of phase 2/3 trials for new
    anti-cancer treatments are single arm?

  • If you need expert statisticians to give a meaning to your clinical trials, it means the drug is either not working, or it is not worth

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy